Baytril Flavour Tablets from Bayer are available in Baytril Flavour Tablets 15 mg, Baytril Flavour Tablets 50 mg, Baytril Flavour Tablets 150 mg, Baytril Flavour Tablets 250 mg; containing 15mg, 50mg, 150mg or 250mg of enrofloxacin for oral administration to dogs and cats. Baytril Oral Solutions are also available in Baytril 2.5% Oral Solution (containing 25mg enrofloxacin and 14mg benzyl alcohol per ml) and Baytril 10% Oral Solution (containing 100mg enrofloxacin and 14mg benzyl alcohol per ml).
Baytril 50mg flavour tablets contain 50mg of enrofloxacin per tablet which is a synthetic, broad spectrum antimicrobial substance, belonging to the fluoroquinolone group. Indicated for use... [More info]
Baytril 150mg flavour tablets contain 150mg of enrofloxacin per tablet which is a synthetic, broad spectrum antimicrobial substance, belonging to the fluoroquinolone group of antibiotics.... [More info]
Baytril Flavour 25mg/ml Oral Suspension For Cats is for the treatment of single or mixed bacterial infections of the respiratory, ailmentary and urinary tract, skin or wounds caused by the... [More info]
Baytril 10% Oral Solution is indicated for use in turkeys, and poultry, specifically broiler chickens, broiler breeders and pullets being reared as layers. It is for use in the treatment of... [More info]
Baytril Flavour Tablets 15mg, 50 mg 150 mg and 250 mg are light brown to brown, slightly marbled, round, scored, flavoured tablets containing 50 mg, 150 mg or 250 mg enrofloxacin for oral administration to dogs.
Enrofloxacin is a synthetic, broad spectrum antimicrobial substance, belonging to the fluoroquinolone group of antibiotics. It is bactericidal in action and effective against many gram positive and gram negative bacteria and mycoplasmas. The product is for use in dogs and cats in the treatment of bacterial infections of the alimentary, respiratory and urogenital tracts, skin, secondary wound infections and otitis externa where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.
The dose rate of enrofloxacin is 5 mg/kg given orally once daily or as a divided dose twice daily for 3 to 10 days with or without food. Treatment may be initiated with Baytril 5% Solution for Injection or Baytril 2.5% Solution for Injection and maintained with Baytril Flavour Tablets. The daily dose is achieved as follows: Cats and small dogs: Baytril 15 mg – 1 tablet per 3 kg bodyweight, Medium dogs: Baytril 50 mg – 1 tablet per 10 kg bodyweight, Large dogs: Baytril 150 mg – 1 tablet per 30 kg bodyweight, Extra large dogs: Baytril 250 mg – 1 tablet per 50 kg bodyweight – Tablets can be halved to achieve the appropriate dose in dogs above 50 kg.
The product may be used safely in pregnant and lactating animals.
Contra-indications, warnings, etc. Baytril flavour tablets should not be used for prophylaxis. Not for use in dogs less than 1 year of age or in exceptionally large breeds of dog with a longer growth period under 18 months of age, as articular cartilage may be affected during the period of rapid growth. Not recommended for use in cats less than 8 weeks of age. Do not exceed the recommended dose. In accidental overdose, vomiting, diarrhoea, and CNS/behavioural changes may occur. There is no antidote and treatment should be symptomatic. In cats, retinotoxic effects including blindness can occur when the recommended dose is exceeded. In target animal studies, cats have been shown to suffer ocular damage after receiving doses of more than 15 mg/kg once daily for 21 consecutive days. Doses of 30 mg/kg given once daily for 21 consecutive days have been shown to cause irreversible ocular damage. At 50 mg/kg given once daily for 21 consecutive days, blindness can occur.
Pharmaceutical precautions; Do not store above 25°C. Store in a dry place. Return any halved 250 mg Tablets to the opened blister and use within 7 days.Unused product or waste material should be disposed of in accordance with current practice for pharmaceutical waste under national waste disposal regulations.
Enrofloxacin is a synthetic, broad spectrum antimicrobial substance, belonging to the fluoroquinolone group of antibiotics. Enrofloxacin is bactericidal in action with activity against Gram positive and Gram negative bacteria and mycoplasmas. The mechanism of action of the quinolones is unique among antimicrobials – they act primarily to inhibit bacterial DNA gyrase, an enzyme responsible for controlling the supercoiling of bacterial DNA during replication. Resealing of the double standard helix is inhibited resulting in irreversible degradation of the chromosomal DNA. The fluoroquinolones also possess activity against bacteria in the stationary phase by an alteration of the permeability of the outer membrane phospholipid cell wall.
The pharmacokinetics of enrofloxacin are such that oral and parenteral administration lead to similar serum levels. Enrofloxacin possesses a high distribution volume. Tissue levels 2–3 times higher than that found in the serum have been demonstrated in laboratory animals and target species. Organs in which high levels can be expected are the lungs, liver, kidney, skin, bone, and lymphatic system. Enrofloxacin also distributes into the C.S.F., the aqueous humour, and the foetus in pregnant animals.